The opposing effects of CCN2 and CCN5 on the development of cardiac hypertrophy and fibrosis

Journal of Molecular and Cellular Cardiology

Volumn 49, Issue 2, 2010, Pages 294-303

  Yoon, Pyoung Oh ^a   Lee, Min Ah ^a   Cha, Hyeseon ^a   Jeong, Moon Hee ^a   Kim, Jooyeon ^a   Jang, Seung Pil ^a   Choi, Bo Youn ^a   Jeong, Dongtak ^b   Yang, Dong Kwon ^a   Hajjar, Roger J ^b   Park, Woo Jin ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Cardiac hypertrophy; CCN2; CCN5; SMAD; TGF

Indexed keywords

CELL PROTEIN; CONNECTIVE TISSUE GROWTH FACTOR; PHENYLEPHRINE; PROTEIN CCN5; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; HEART FUNCTION; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE OVERLOAD; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RISK FACTOR;

ANIMALS; CARDIOMEGALY; CELLS, CULTURED; CONNECTIVE TISSUE GROWTH FACTOR; FIBROSIS; HEART FAILURE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, TRANSGENIC; MYOCARDIUM; MYOCYTES, CARDIAC; PHENYLEPHRINE; PRESSURE; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

MUS; MUS MUSCULUS;

EID: 77953701817     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.04.010     Document Type: Article

References (39)

1. Hunter J.J., Chien K.R. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 1999, 341(17):1276-1283.
2. Katz A.M. The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart. Ann Intern Med 1994, 121(5):363-371.
3. Berenji K., Drazner M.H., Rothermel B.A., Hill J.A. Does load-induced ventricular hypertrophy progress to systolic heart failure?. Am J Physiol Heart Circ Physiol 2005, 289(1):H8-H16.
4. Molkentin J.D., Dorn G.W. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 2001, 63:391-426.
5. Perbal B. CCN proteins: multifunctional signalling regulators. Lancet 2004, 363(9402):62-64.
6. Bornstein P., Sage E.H. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 2002, 14(5):608-616.
7. Chen M.M., Lam A., Abraham J.A., Schreiner G.F., Joly A.H. CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol 2000, 32(10):1805-1819.
8. Blom I.E., Goldschmeding R., Leask A. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy?. Matrix Biol 2002, 21(6):473-482.
9. Matsui Y., Sadoshima J. Rapid upregulation of CTGF in cardiac myocytes by hypertrophic stimuli: implication for cardiac fibrosis and hypertrophy. J Mol Cell Cardiol 2004, 37(2):477-481.
10. Ohnishi H., Oka T., Kusachi S., Nakanishi T., Takeda K., Nakahama M., et al. Increased expression of connective tissue growth factor in the infarct zone of experimentally induced myocardial infarction in rats. J Mol Cell Cardiol 1998, 30(11):2411-2422.
11. Yun S.H., Shin J.O., Lim B.K., Kim K.L., Gil C.O., Kim D.K., et al. Change in the cells that express connective tissue growth factor in acute Coxsackievirus-induced myocardial fibrosis in mouse. Virus Res 2007, 126(1-2):62-68.
12. Hayata N., Fujio Y., Yamamoto Y., Iwakura T., Obana M., Takai M., et al. Connective tissue growth factor induces cardiac hypertrophy through Akt signaling. Biochem Biophys Res Commun 2008, 370(2):274-278.
13. Panek A.N., Posch M.G., Alenina N., Ghadge S.K., Erdmann B., Popova E., et al. Correction: connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload. PLoS ONE 2009, 4(9).
14. Zhang R., Averboukh L., Zhu W., Zhang H., Jo H., Dempsey P.J., et al. Identification of rCop-1, a new member of the CCN protein family, as a negative regulator for cell transformation. Mol Cell Biol 1998, 18(10):6131-6141.
15. Delmolino L.M., Stearns N.A., Castellot J.J. COP-1, a member of the CCN family, is a heparin-induced growth arrest specific gene in vascular smooth muscle cells. J Cell Physiol 2001, 188(1):45-55.
16. Pennica D., Swanson T.A., Welsh J.W., Roy M.A., Lawrence D.A., Lee J., et al. WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A 1998, 95(25):14717-14722.
17. Lake A.C., Castellot J.J. CCN5 modulates the antiproliferative effect of heparin and regulates cell motility in vascular smooth muscle cells. Cell Commun Signal 2003, 1(1):5.
18. Lake A.C., Bialik A., Walsh K., Castellot J.J. CCN5 is a growth arrest-specific gene that regulates smooth muscle cell proliferation and motility. Am J Pathol 2003, 162(1):219-231.
19. Mason H.R., Lake A.C., Wubben J.E., Nowak R.A., Castellot J.J. The growth arrest-specific gene CCN5 is deficient in human leiomyomas and inhibits the proliferation and motility of cultured human uterine smooth muscle cells. Mol Hum Reprod 2004, 10(3):181-187.
20. Frazier K., Williams S., Kothapalli D., Klapper H., Grotendorst G.R. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 1996, 107(3):404-411.
21. Kireeva M.L., Latinkic B.V., Kolesnikova T.V., Chen C.C., Yang G.P., Abler A.S., et al. Cyr61 and Fisp12 are both ECM-associated signaling molecules: activities, metabolism, and localization during development. Exp Cell Res 1997, 233(1):63-77.
22. Brigstock D.R. The CCN family: a new stimulus package. J Endocrinol 2003, 178(2):169-175.
23. Ball D.K., Surveyor G.A., Diehl J.R., Steffen C.L., Uzumcu M., Mirando M.A., et al. Characterization of 16- to 20-kilodalton (kDa) connective tissue growth factors (CTGFs) and demonstration of proteolytic activity for 38-kDa CTGF in pig uterine luminal flushings. Biol Reprod 1998, 59(4):828-835.
24. Yang D.K., Choi B.Y., Lee Y.H., Kim Y.G., Cho M.C., Hong S.E., et al. Gene profiling during regression of pressure overload-induced cardiac hypertrophy. Physiol Genomics 2007, 30(1):1-7.
25. Sadoshima J., Jahn L., Takahashi T., Kulik T.J., Izumo S. Molecular characterization of the stretch-induced adaptation of cultured cardiac cells. An in vitro model of load-induced cardiac hypertrophy. J Biol Chem 1992, 267(15):10551-10560.
26. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322(22):1561-1566.
27. Katz A.M. Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure. N Engl J Med 1990, 322(2):100-110.
28. Hardt S.E., Sadoshima J. Negative regulators of cardiac hypertrophy. Cardiovasc Res 2004, 63(3):500-509.
29. Chen Y., Abraham D.J., Shi-Wen X., Pearson J.D., Black C.M., Lyons K.M., et al. CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin. Mol Biol Cell 2004, 15(12):5635-5646.
30. Abreu J.G., Ketpura N.I., Reversade B., De Robertis E.M. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 2002, 4(8):599-604.
31. Bork P. The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett 1993, 327(2):125-130.
32. McDonald N.Q., Hendrickson W.A. A structural superfamily of growth factors containing a cystine knot motif. Cell 1993, 73(3):421-424.
33. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004, 63(3):423-432.
34. Rosenkranz S., Flesch M., Amann K., Haeuseler C., Kilter H., Seeland U., et al. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol 2002, 283(3):H1253-H1262.
35. Zhao X.Y., Zhao L.Y., Zheng Q.S., Su J.L., Guan H., Shang F.J., et al. Chymase induces profibrotic response via transforming growth factor-beta 1/Smad activation in rat cardiac fibroblasts. Mol Cell Biochem 2008, 310(1-2):159-166.
36. Sakata Y., Chancey A.L., Divakaran V.G., Sekiguchi K., Sivasubramanian N., Mann D.L. Transforming growth factor-beta receptor antagonism attenuates myocardial fibrosis in mice with cardiac-restricted overexpression of tumor necrosis factor. Basic Res Cardiol 2008, 103(1):60-68.
37. Heger J., Peters S.C., Piper H.M., Euler G. SMAD-proteins as a molecular switch from hypertrophy to apoptosis induction in adult ventricular cardiomyocytes. J Cell Physiol 2009, 220(2):515-523.
38. Frantz S., Hu K., Adamek A., Wolf J., Sallam A., Maier S.K., et al. Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol 2008, 103(5):485-492.
39. Petrov V.V., Fagard R.H., Lijnen P.J. Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension 2002, 39(2):258-263.